Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 12/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593324 | 0.85 | AKR1C3 (0.59) | KMT2ANPC1RAB9ACES2CES1 | |
| SCHEMBL7408864 | 0.85 | CES2 (0.47) | KMT2AMEN1NPC1RAB9ACES2 | |
| SCHEMBL16952658 | 0.85 | NPC1 (0.43) | KMT2AMEN1MAOBNPC1RAB9A | |
| SCHEMBL5331403 | 0.84 | MAOB (0.53) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL7771074 | 0.84 | CES2 (0.46) | KMT2AMEN1MAOBNPC1RAB9A | |
| SCHEMBL7771077 | 0.84 | PARP1 (0.66) | CES2CES1L3MBTL1 | |
| SCHEMBL29742938 | 0.84 | MAOB (0.55) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL697586 | 0.84 | MAOB (0.55) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL21658556 | 0.84 | CES2 (0.46) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL23343631 | 0.82 | SMN1; SMN2 (0.54) | KMT2AMEN1NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1902012-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALKYLPHENOLS | BASF SE (DE) | 2015-12-09 | — | — | EP | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-7968328-B2 | Method for producing optically active aminoalkylphenols | BASF SE (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20100209980-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALKYLPHENOLS | BASF AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-1902012-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALKYLPHENOLS | BASF SE (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006136538-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALKYLPHENOLS | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | KMT2A 3072/4885MEN1 2496/4885MAOB 1686/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | KMT2A 3072/4885MEN1 2496/4885MAOB 1686/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | KMT2A 3072/4885MEN1 2496/4885MAOB 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.